Contineum Therapeutics: Phase 2 MOONLIGHT-1 of JNJ-5120/PIPE-307 fails primary endpoint; drug well-tolerated
Contineum Therapeutics reported that the Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 did not meet its primary efficacy endpoint, though the drug was well-tolerated with no new safety signals.Key Highlights:Original SEC Filing: Contineum Therapeutics, Inc. [ CTNM ] - 8-K - Sep. 14, 2026This is an…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.